Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allurion Technologies, Inc. filings document the company’s medical-device weight-loss business, securities, and public-company status. Recent Form 8-K reports cover FDA PMA approval for the Allurion Gastric Balloon System featuring the Allurion Smart Capsule, selected preliminary financial results, warrant exercise inducement agreements, and NYSE continued-listing notices affecting the company’s common stock and warrants.
The filing record also includes proxy and annual-meeting disclosures for board elections, auditor ratification, equity incentive plan amendments and other shareholder voting matters. Form 12b-25 reporting documents delayed quarterly-report timing, while capital-structure disclosures describe common stock, warrants, exercise prices, stockholder approval mechanics and beneficial-ownership limitations.
Allurion Technologies, Inc. reported a change in its external auditor and reiterated previously disclosed weaknesses in its financial controls. The Audit Committee dismissed Deloitte & Touche LLP as independent registered public accounting firm effective May 22, 2026, after Deloitte had audited the company since 2016. Deloitte’s reports on the fiscal years ended December 31, 2024 and 2025 contained no adverse opinions or qualifications, and the company states there were no disagreements with Deloitte on accounting, disclosure, or audit scope.
The company did, however, report material weaknesses in internal control over financial reporting for 2024, 2025 and the interim period through May 22, 2026. These relate to insufficient segregation of duties in the close process, inadequate staffing with public company and technical accounting expertise, and insufficient information systems controls around access and change management. On May 20, 2026, the Audit Committee appointed CBIZ CPAs P.C. as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
Allurion Technologies reported a challenging first quarter of 2026. Revenue was $2.9 million, down from $5.6 million a year earlier, as sales declined across several geographies. The company posted a net loss of $6.1 million compared with a $1.5 million loss in the prior-year quarter, partly driven by a $4.1 million warrant inducement expense.
Cash and cash equivalents were $5.1 million as of March 31, 2026, while total assets were $14.0 million against total liabilities of $91.9 million, resulting in a stockholders’ deficit of $77.9 million. The balance sheet includes a $48.8 million Revenue Interest Financing liability and $28.6 million of RTW Convertible Notes, both carried at fair value.
Management discloses substantial doubt about Allurion’s ability to continue as a going concern within one year, citing recurring operating losses, negative operating cash flows, covenant noncompliance under its credit facilities, and the need for additional capital. Cost reductions from prior restructuring actions sharply lowered operating expenses, but they did not offset weaker revenue and financing-related fair value movements.
Allurion Technologies, Inc. describes its business as a metabolically focused weight loss platform built around the Allurion Program, which combines the swallowable Allurion Smart Capsule gastric balloon with an AI-powered Virtual Care Suite for remote monitoring and behavior change.
The company highlights more than 200,000 patients treated across over 50 countries and positions its program as complementary to GLP-1 drugs. It reports FDA PMA approval in the United States for the Allurion Gastric Balloon System for adults with obesity, enabling U.S. commercialization. Recent financing steps include a November 2025 private placement and a February 2026 warrant inducement that raised cash but added new warrants.
Allurion also discloses NYSE minimum market-capitalization non-compliance and ongoing appeals of delisting determinations, with its common stock now trading on the OTC market and plans to seek a higher-tier OTC listing. The company emphasizes a large obesity market opportunity, a broad patent and trademark portfolio, and a strategy focused on global expansion, U.S. launch, and a path to profitability.
Allurion Technologies received notice that the New York Stock Exchange will begin proceedings to delist its common stock and warrants after the company failed to meet the NYSE rule requiring an average global market capitalization of at least $15,000,000 over 30 consecutive trading days. Trading on the NYSE was suspended after market close on March 6, 2026, and the shares now trade on the OTCID Market under the same symbols while Allurion appeals the decision.
The company recently obtained U.S. FDA approval for its Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, and has presented the NYSE with a multi-step plan to regain compliance or qualify for listing on NYSE American, strengthen its balance sheet, and fund U.S. commercialization of the Smart Capsule. Management cautions there is no assurance the appeal or relisting efforts will succeed, and notes that liquidity, trading volume and broker quoting on the OTC market may be limited.
Allurion Technologies, Inc. large shareholder RTW-affiliated entities filed an amended Schedule 13D to update their beneficial ownership of the company’s common stock.
RTW Investments, LP and Roderick Wong report beneficial ownership of 5,891,430 shares, representing 39.4% of Allurion’s common stock, with shared voting and dispositive power. RTW Master Fund, Ltd holds 3,138,798 shares (21.0%), and RTW Innovation Master Fund, Ltd holds 2,427,089 shares (16.2%), all on a shared basis.
The ownership percentages are calculated from shares outstanding reported in a January 2026 prospectus plus additional shares issued under an Inducement Offer to Exercise Common Stock Purchase Warrants that closed on February 26, 2026. The filing states that no transactions in Allurion securities were made by the reporting persons in the past sixty days and that the higher percentage figures reflect an increase in Allurion’s outstanding shares.
Allurion Technologies reported that the New York Stock Exchange plans to begin delisting proceedings because the company no longer meets the NYSE rule requiring at least $50 million in stockholders’ equity or a $50 million average market value. Allurion will appeal this determination to an NYSE board committee, and its common stock and warrants are expected to continue trading on the NYSE during the review period, provided it meets other listing requirements.
The company is pursuing several steps to regain compliance or qualify for listing on another exchange, including capital-raising efforts, negotiations with creditors and security holders, an agreement to exchange all outstanding debt for preferred stock at a premium to the current share price, and a recent warrant inducement transaction. Management warns that there is no assurance the appeal or these initiatives will succeed, and notes that any ultimate delisting could reduce liquidity, pressure the share price, limit access to public capital markets, and weaken its ability to grant equity incentives.
Allurion Technologies entered into a warrant exercise inducement agreement with certain existing warrant holders. The company cut the exercise price of its outstanding warrants to $1.15 per share and the participating holders agreed to exercise warrants for an aggregate 2,659,565 shares of common stock.
In return, Allurion will issue new warrants to these holders to purchase up to 5,319,130 additional shares of common stock at $1.15 per share. The company expects to receive approximately $3.0 million in gross cash proceeds from the warrant exercises. The new warrants will become exercisable after stockholder approval, will expire five years after that date, and are subject to beneficial ownership limits of 4.99% or 9.99% at the holders’ option.
Allurion engaged Roth Capital Partners as financial advisor and will pay a fee equal to 5.0% of the gross proceeds from the warrant exercises, plus up to $40,000 for related expenses. The company also agreed to file a registration statement to cover resale of shares underlying the new warrants within 60 days of the inducement letter.
Allurion Technologies reported that the U.S. Food and Drug Administration granted premarket approval for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, for adults aged 22–65 with obesity and a BMI between 30 and 40 kg/m2 after at least one unsuccessful weight-loss attempt.
The Smart Capsule is swallowed in a brief office visit, forms a gastric balloon that remains in the stomach for about four months, then empties and passes naturally, with the option for a second capsule within a 10‑month treatment period. Allurion estimates this indication provides access to roughly 80 million Americans within the approved BMI range.
The company highlights prior use of the Smart Capsule outside the United States in over 200,000 patients and cites published data showing around 14% total body weight loss with one balloon cycle and over 20% with two cycles or when combined with low‑dose GLP‑1 therapies. Allurion also notes risks around maintaining FDA approval, successful commercialization, and obtaining sufficient financing to continue as a going concern.
Allurion Technologies, Inc. has registered 5,988,024 shares of common stock for potential resale by existing securityholders. The shares include 2,994,012 shares issued in a November 2025 private placement and 2,994,012 shares issuable upon exercise of accompanying warrants with a $1.67 exercise price. The company will not receive proceeds from any resale of these shares but could receive up to approximately $5.0 million if all November 2025 warrants are exercised for cash. As of January 5, 2026, 12,279,181 shares of common stock were outstanding. The prospectus notes that large or sustained resales could put pressure on the stock price. Allurion remains an emerging growth and smaller reporting company and highlights recent financing steps and an exchange agreement with RTW tied to Series B preferred stock and specified performance conditions.